Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy

  • ALLO-715 Utilizes Gene-Editing of TRAC and CD52 Loci to Enable Allogeneic CAR T Therapy
  • ALLO-715 will be Evaluated in Combination with ALLO-647, Allogene’s Proprietary anti-CD52 Antibody as Part of the Lymphodepletion Regimen 
  • Allogene Plans to Initiate the UNIVERSAL Study for ALLO-715 in Relapsed/Refractory Multiple Myeloma in the Second Half of 2019

SOUTH SAN FRANCISCO, CA, USA I June 04, 2019 I Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared Allogene’s Investigational New Drug (IND) application for ALLO-715 in patients with relapsed/refractory multiple myeloma. The Phase 1 portion of the UNIVERSAL study, which will include ALLO-647 as part of the lymphodepletion regimen, is expected to be initiated in the second half of 2019.

“We are very pleased to have received clearance for our second IND this year and look forward to initiating the UNIVERSAL trial in 2019,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “We believe an “off-the-shelf” CAR T cell therapy could be game-changing for patients, and we plan to leverage learnings from our ALLO-501 ALPHA trial in non-Hodgkin lymphoma initiated in Q2 2019 to accelerate the development of ALLO-715.”

Multiple myeloma is the second most common hematological malignancy in the United States, with 32,110 new cases and 12,960 deaths estimated in 2019.1

About ALLO-715
ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies. Multiple myeloma is characterized by abnormalities in plasma cells that reproduce uncontrollably in the bone marrow of people with the disease,2 multiple myeloma is incurable for most patients, and most patients relapse despite the treatments available.3  Preclinical study results for ALLO-715 were published in the journal Molecular Therapy validating the potential for an AlloCAR T to treat multiple myeloma and demonstrating the ability for ALLO-715 to sustain potent anti-tumor responses in pre-clinical models. Allogene expects completion of site initiation activities, production of additional ALLO-715 clinical supply, and initiation of the UNIVERSAL study in the second half of 2019.

ALLO-715 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the BCMA target. Allogene holds the global development and commercial rights for this investigational candidate.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit, and follow @AllogeneTx on Twitter and LinkedIn.

1 U.S. SEER database
2 Multiple myeloma - Genetics Home Reference - NIH. Retrieved from
3 Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406

SOURCE: Allogene Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up